Benny, you're being a bit naughty again.
You keep saying that NYR-BIO3 operates downstream of glutamate receptors. That's not really true, is it.
You mean it's downstream of
metabotropic glutamate receptors.
But targeting ionotropic glutamate receptors is showing much more promise. Here's a recent review article highlighting at least 30 different novel compounds that show more promise than NYR-BIO3, with a broader action, most of them with ACTUAL proven safety in humans.
https://onlinelibrary.wiley.com/doi/full/10.1002/nep3.46
(20min delay)